Resource Library
From cell line development to upstream optimization: Enhancing biologics quality and productivity
To ensure optimal glycosylation, we apply high-throughput lectin assays during early clone selection to identify the best candidates for antibody production. These clones are further optimized through a modular glycosylation platform and Design-of-Experiment (DoE) strategies, allowing for precise control of ADCC and CDC functions in Upstream Process development. This integrated approach ensures both high productivity and enhanced therapeutic performance.
In this webinar, we will explain how Samsung Biologics integrates these advanced CLD and USP strategies to optimize both productivity and therapeutic effectiveness, ensuring the development of high-quality biologics.
Key learning objectives:
- Understand how Samsung Biologics achieves high titer, purity, and stability in CLD using the transposase integration system, with further productivity gains through S-Tensify™
- Learn how we enhance antibody functionality with the S-AfuCHO™ cell line, enabling the production of fucose-free antibodies to improve ADCC activity
- Discover how Samsung Biologics optimizes glycosylation control from early clone selection using high-throughput lectin assays and modular glycosylation platforms to improve therapeutic efficacy
To ensure optimal glycosylation, we apply high-throughput lectin assays during early clone selection to identify the best candidates for antibody production. These clones are further optimized through a modular glycosylation platform and Design-of-Experiment (DoE) strategies, allowing for precise control of ADCC and CDC functions in Upstream Process development. This integrated approach ensures both high productivity and enhanced therapeutic performance.
In this webinar, we will explain how Samsung Biologics integrates these advanced CLD and USP strategies to optimize both productivity and therapeutic effectiveness, ensuring the development of high-quality biologics.
Key learning objectives:
- Understand how Samsung Biologics achieves high titer, purity, and stability in CLD using the transposase integration system, with further productivity gains through S-Tensify™
- Learn how we enhance antibody functionality with the S-AfuCHO™ cell line, enabling the production of fucose-free antibodies to improve ADCC activity
- Discover how Samsung Biologics optimizes glycosylation control from early clone selection using high-throughput lectin assays and modular glycosylation platforms to improve therapeutic efficacy
